- Biotech on the Web - https://biotechontheweb.com -

NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview


BrainStorm Cell Therapeutics [1] released new data on potential biomarkers from its Phase 2 trial investigating NurOwn [2], the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND [3] meeting held in Boston last week.

Both these findings and an ongoing Phase 3 trial, now recruiting patients in the U.S., were discussed in greater detail with Ralph Kern, MD, Brainstorm’s chief operating officer and chief medical officer, in an interview to ALS News Today [4] days before the Dec. 8–10 symposium.

NurOwn  [5]is an autologous adult stem cell therapy technology [6] that uses a patient’s own stem cells — specifically, bone marrow-derived mesenchymal stem cells (MSC) — and differentiates them into neuron-supporting cells.

Its cells work by secreting nerve-growth factors known to protect existing motor neurons and promote motor neuron growth, with the potential of helping to re-establish nerve-muscle interaction.

More at: https://alsnewstoday.com/2017/12/12/brainstorm-cmo-talks-in-interview-about-nurown-and-potential-as-therapy-for-als-with-rapid-progression/